Sickle Cell Disease

Sangamo gets federal grant to apply ZFP technology

Published in Gene Therapy Weekly, September 26th, 2002

Sangamo BioSciences, Inc., (SGMO) announced that the company has been awarded a $1 million NIH grant to conduct research on the application of Sangamo's zinc finger DNA binding transcription factor (ZFP TF) technology in the development of a treatment for sickle cell disease in collaboration with researchers at the University of Alabama, Birmingham.

The grant, entitled "Transactivation of Fetal Hemoglobin Genes for the Treatment of Sickle Cell Disease," was awarded by the National Heart, Lung and Blood Institute and will be paid out over a 4-year period. Investigators at Sangamo and UAB will work collaboratively to target fetal hemoglobin genes with engineered ZFP...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry